Form 8-K - Current report:
SEC Accession No. 0001493152-24-048734
Filing Date
2024-12-05
Accepted
2024-12-04 19:57:34
Documents
17
Period of Report
2024-12-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43349
2 ex10-1.htm EX-10.1 72415
3 ex10-2.htm EX-10.2 60390
4 ex10-3.htm EX-10.3 110920
  Complete submission text file 0001493152-24-048734.txt   503801

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20241202.xsd EX-101.SCH 3027
6 XBRL LABEL FILE pvct-20241202_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE pvct-20241202_pre.xml EX-101.PRE 24173
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3363
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 241527492
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)